|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.23 HKD | +1.95% |
|
0.00% | -21.23% |
| 05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
| 04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
Alphamab Oncology reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 136.47 million compared to CNY 53.57 million a year ago. Net loss was CNY 39.86 million compared to CNY 147.31 million a year ago.
Basic loss per share from continuing operations was CNY 0.04 compared to CNY 0.16 a year ago. Diluted loss per share from continuing operations was CNY 0.04 compared to CNY 0.16 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.23% | 633M | |
| +18.19% | 47.02B | |
| +48.77% | 41.86B | |
| +1.13% | 41.76B | |
| -4.27% | 28.8B | |
| +11.27% | 26.05B | |
| -21.14% | 19.15B | |
| +4.92% | 12.55B | |
| +27.41% | 12.34B | |
| -3.88% | 11.82B |
ALPHAMAB ONCOLOGY 
